prothrombinase enzyme complex. Although potentiating endothelial responses to the terminal complement proteins, anti-CD59 had no effect on the response of these cells to stimulation by histamine. Taken together, these data suggest that human endothelial cells express the CD59 cell surface inhibitor of the terminal complement proteins, which serves to protect these cells from poreforming and cell-stimulatory effects of the C5b-9 complex. These data also suggest that the inactivation or deletion of this cell surface regulatory molecule would increase the likelihood for procoagulant changes in endothelium exposed to complement activation in plasma.
T lished as mediators of immune destruction of microorganisms and transplanted heterologous tissue. In addition, when deposited on homologous blood and vascular cell membranes, these proteins have been shown to induce the nonlytic activation of a variety of cell responses, through pathways that appear to involve influx of extracellular calcium and activation of intracellular protein kinase C (PKC).1-4 For example, human endothelial cells exposed to the human C5b-9 proteins exhibit an increase in cytosolic calcium concentration, which is accompanied by induced secretion of their intracellular storage granules containing von Willebrand factor ( v W F ) .~ In addition to inducing secretory fusion of the Weibel-Palade bodies with the plasma membrane, exposure to C5b-9 induces vesiculation of the endothelial cell surface, exposing binding sites for coagulation factor Va, and thereby increasing membrane-catalyzed prothrombinase activity of this normally nonthrombogenic Cellular resistance to the effects of the C5b-9 proteins can occur through a variety of mechanisms, including membrane and fluid phase inhibitors that block their assembly and membrane insertion, as well as compensatory cellular rece11.4
~~ ~ sponses, including vesiculation and endocytosis, which serve to remove these plasma membrane-inserted proteins from the cell surface.4-" Recently, a membrane protein that inhibits C5b-9-mediated hemolysis has been identified in human erythrocyte^.'^*'^ This 18-to 21-Kd protein has been sequenced and found to be identical to leukocyte CD59, a glycosyl-phosphatidylinositol-linked membrane protein distributed on lymphocytes, neutrophils, and monocyte^.'^.'^ Although CD59 has not been detected in human platelets, antibody raised against this protein has been shown to augment C9 activation by membrane C5b-8, and to potentiate CSb-9-induced platelet activation responses.15 These data imply the presence of a C5b-9 inhibitor on the surface of these cells that shares epitopes with CD59. We now report evidence for a C5b-9-inhibitory protein on the surface of human endothelial cells that is antigenically related or identical to CD59, and that serves to protect these cells from stimulatory effects arising through complement activation.
EXPERIMENTAL PROCEDURES
As described previously,' human umbilical vein endothelial cells (HUVE) were harvested using 0.1% collagenase, and grown in Medium 199 containing 20% fetal bovine serum (FBS), heparin, endothelial growth supplement, and penicillin and streptomycin until confluent. Cells were subcultured using trypsin after reaching confluence. First passage cells were grown in 48-well (1 cm') or 96-well (0.3 cmZ) tissue culture plates and used 2 to 5 days after subculturing. Rabbits were immunized with partially purified human endothelial cell plasma membranes. The details of membrane preparation, immunization, and immunoglobulin G (IgG) purification have been reported previously.'
Preparation of serum deficient in the complement component C8. Human serum was depleted of C8 by absorption against rabbit antibody to C8 coupled to agarose, as described previously.'
Purification of human complement proteins C8 and C9. Human C8 and C9 were purified as reported previously.' These proteins were iodinated to specific activities of 2,501 cpm/ng (C8) and 1,454 cpm/ng (C9) using immobilized lactoperoxidase and glucose oxidase (Enzymobead Radioiodination Reagent; BioRad, Richmond, CA).
Purification of an 18-to 21-Kd inhibitor of C5b-9 from human erythrocyte membranes. Isolation of the 18-to 21-Kd inhibitor Endothelial cell culture.
Preparation of rabbit anti-endothelial cell antibody.
ENDOTHELIAL CELL COMPLEMENT C5B-9 INHIBITOR 2573 from erythrocyte membranes (P18), preparation of rabbit antibody to the erythrocyte inhibitor (anti-P18), and preparation of Fab fragments of anti-P18 IgG have been reported previously in The full-length sequence of the 18-to 21-Kd erythrocyte inhibitor has been reported and has established its identity with the leukocyte antigen CD59.I3 Therefore, the antibody against the erythrocyte inhibitor, previously referred to as anti-P18, will be designated anti-CD59 henceforth. Monoclonal antibodies (MoAbs) 1 F1 and 1F5, reactive with CD59, were provided by Drs Motowo Tomita (Showa University, Tokyo, Japan) and Hidechika Okada (Nagoya City University School of Medicine, Nagoya, Japan).
Radioiodination of antibodies. MoAbs 1F1 and 1F5 were radiolabeled with IODO-GEN (Pierce Chemical, Rockford, IL). Specific activities were 6,221 cpm/ng (1F1) and 4,856 cpm/ng ( I F5).
Binding of radiolabeled antibodies to CD59 to cultured human endothelial cells. Except where specified, all cell experiments were performed using Hanks balanced salt solution, modified to contain 10 mmol/L HEPES and 1% bovine serum albumin (Hanks-HEPES-BSA). Cells were washed free of serum-containing medium and fixed 10 minutes with 1% paraformaldehyde in phosphate-buffered saline, pH 7.4. Cells were washed three times to remove fixative, and incubated with '251-anti-CD59, '251-lFl, or '251-1F5 in the presence and absence of a 20-fold excess of the unlabeled antibody for 30 minutes at room temperature. Cells were then washed rapidly five times with 1 mL vol of Hanks-HEPES-BSA chilled to 4"C, solubilized in 4% sodium dodecyl sulfate (SDS), and radioactivity measured.
Immunoblotting of endothelial proteins with antibody to CDS9. Second-passage HUVE were grown to confluence (75 cm'). After washing free of medium, cells were removed by scraping. The washed cells were pelleted, denatured at 100°C in 10% SDS and 20 mmol/L N-ethylmaleimide (without reduction), and subjected to 15% polyacrylamide gel electrophoresis under nonreducing conditions. After transfer to nitrocellulose and blocking with 10% nonfat dry milk, blots were incubated overnight with either polyclonal anti-CD59 (10 pg/mL) or MoAb IF1 (IO pg/mL) and developed with affinity-purified goat antirabbit IgG or goat antimouse IgG conjugated to alkaline phosphatase (Sigma, St Louis, MO). Purified human erythrocyte CD59 served as molecular weight standard. Confluent endothelial cells were washed three times with Hanks-HEPES-BSA. The cells were then incubated with rabbit anti-endothelial IgG ( 5 mg/mL) for 15 minutes at 23"C, washed once, and incubated with C8-deficient serum for 10 minutes at 37°C. The cells were then washed three times with buffer chilled to 4"C, and incubated with antLCD59 (IgG or Fab fragments) or Hanks-HEPES-BSA only (see figure legends) at 4°C for 30 minutes. Finally, cells were washed twice and incubated at 37°C with C8 and/or C9 at the concentrations described in the figure legends. In some experiments, radiolabeled C8 or C9 was used to measure cell surface binding (see legend to Fig 6) .
Quantitation of CSb-9-induced changes in membrane permeability using 3H-2-deoxy-Dglucose (-'H-DOGJ. For 24 hours before an experiment, cells were grown in culture medium (300 p L ) containing 3H-DOG (ICN Radiochemicals, Irvine, CA, 33 Ci/mmol/L) 4 &/well for 24 hours. Cells were then washed and complement complexes assembled as described above, including incubation with antLCD59 IgG (0 to 1 mg/mL) before addition of C8 and C9. Ten minutes after addition of C8 and/or C9, supernatants were removed and pooled with two subsequent washes (100 pL). Cells were lysed with 125 PL of 2% Triton X-100 (Calbiochem, San Diego, CA), each well was washed twice, and washes pooled with lysates. Supernates and lysates were counted after addition of 4 mL of Aquasol (New England Nuclear Research Products, Boston, MA).
Complement assembly on human endothelial cells.
Assay ofprothrombinase activity. Complement-induced changes in the ability of the endothelial membrane to support assembly of the prothrombinase enzyme complex was assayed as reported previ~usly.~ Briefly, after complement assembly, bovine prothrombin, factor Va, and factor Xa were added in the final concentrations of 1.4 pmol/L, 2 nmol/L, and 10 pmol/L, respectively. After a 6-minute incubation, aliquots were removed and the reaction terminated using EDTA. Thrombin generation was assayed using the synthetic substrate Spectrozyme TH (American Diagnostica, Greenwich, CT) .
After complement assembly, supernatants were removed and assayed for released vWF by methods previously described." Pooled normal human plasma was used as the standard, and results were expressed in units per milliliter where normal pooled plasma is defined as containing 1 U/mL.
Assay for v WFsecretion.

RESULTS
Human erythrocytes, platelets, and leukocytes have been shown to express membrane proteins that serve to restrict activation of the terminal complement proteins at the surface of these cell^.'^-'^ In the case of platelets, neutralization of this C5b-9-regulatory function with an antibody against CD59 has been shown to potentiate complement-induced cell activation. The resistance of human endothelial cells in culture to the pore-forming and cytolytic effects of these proteins suggested the possibility that these cells also express C5b-9-regulatory proteins.'~~ To explore this possibility, we first demonstrated that '251-anti-CD59 (IgG) bound specifically to endothelial monolayers, with saturation observed at 500 pg/mL and half-maximal binding observed at approximately 100 pg/mL (data not shown). Moreover, two MoAbs reactive with erythrocyte CD59 (1F1 and 1F5) were found to bind specifically to the endothelial plasma membrane ( Table  1 ). The presence of CD59 antigen in these cultured human endothelial cells was confirmed by Western blotting with both polyclonal and MoAbs against puried human erythrocyte CD59 (Fig 1) . Immunohistochemical evidence for the expression of the 1F5 epitope on human vascular endothelium has been recently reported by Nose et al. " The binding of these MoAbs at saturation suggests that human endothelial cells in culture express approximately 2 x IO5 molecules of CD59 antigen per cell, equivalent to 100 molecules/pm* of lumenal surface. By comparison, human erythrocytes are estimated to express approximately 25,000 CD59 molecules/ cell, equivalent to approximately 200 molecules/pm2 membrane surface." Whether this endothelial antigen is structurally identical to the 18-to 21-Kd phosphatidylinositol-linked protein isolated from human erythrocytes remains to be determined.
Expression of the CD59 antigen in HUVE. 
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Effect of anti-CD59 on C5b-9 pore formation. The expression of CD59 epitopes by human endothelial cells suggested a complementary C5b-9-regulatory function of the endothelial plasma membrane. We therefore examined whether functionally inhibitory antibody to the CD59 antigen (anti-CD59) altered the assembly and activation of the complement pore on these cells. In these experiments, C5b67 complexes were first deposited on the endothelial plasma membrane, followed by incubation at 4OC with anti-CD59 (IgG or Fab fragments). C5b-9 assembly was then completed by addition of C8 and C9, with incubation at 37OC (see Experimental Procedures). The efflux of 'H-DOG from the endothelial cytoplasm was used to monitor formation of the C5b-9 pore in the plasma membrane. As illustrated by Fig 2, C5b-9 pore formation was potentiated by addition of anti-CD59, with apparent saturation of this effect at 0.5 mg/mL IgG. At the submaximal concentration of C9 used in this experiment, anti-CD59 caused a fourfold increase in the C5b-9-induced efflux of 'H-DOG. By contrast, this antibody had no effect on the efflux of 'H-DOG from C5b-8 cells (omitting C9).
Potentiation of C5b-9 induced stimulatory responses by anti-CD59. The capacity of anti-CD59 to increase the C5b-9-mediated change in plasma membrane permeability (Fig 2) suggested that this antibody might also potentiate the cell-activation responses induced on C5b-9 binding to the endothelial surface. In cells exposed to anti-CD59 (Fab fragments), CSb-9-induced prothrombinase activity was increased approximately threefold when compared with identically treated cells not exposed to antibody (Fig 3) . By contrast, the prothrombinase activity measured for control cells was unaffected by incubation with anti-CD59.
In addition to inducing expression of membrane prothrom- binase sites, the C5b-9 proteins have been shown to stimulate secretion of vWF multimers from endothelial storage granules.' As shown in Fig 4, this secretory response to C5b-9 increased with increasing anti-CD59, and was augmented approximately fourfold at saturating concentrations of Fab (>250 pg/mL). As shown in Fig 5A, antLCD59 (Fab) potentiated the C5b-9-induced secretory response at all concentrations of C9 tested. By contrast, this antibody had no effect on histamine-induced vWF secretion at any concentration of histamine (Fig 5B) . The data of Fig 5 suggest that anti-CD59 potentiates the CSb-9-induced response by directly affecting activation of the complement pore, and does not potentiate receptor-mediated endothelial secretory responses.
The data of Figs 2 through 5, suggest that anti-CD59 specifically inhibits a CSb-9-regulatory protein on the endothelial surface. In red blood cells, CD59 has been shown to restrict hemolysis by C5b-9 and to reduce the incorporation of C9 into membrane C5b-9, thereby decreasing the number of C9 bound to Effect of anti-CD59 on C5b-9 assembly.
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Anti-CD59 Fab (,ug/ml) C5b-8.I6 Therefore, we examined the possibility that the endothelial surface protein recognized by anti-CD59 also affected CSb-9 pore formation by limiting the amount of C9 that can bind to membrane C5b-8. As shown in Fig 6, we were unable to detect any effect of anti-CD59 on the binding of either 1251-C8 to C5b67 or '251-C9 to C5b-8 deposited on the endothelial surface. In these experiments, antLCD59 (Fab) was used at concentrations that maximally augmented CSb-9-induced prothrombinase activity and vWF secretion.
DISCUSSION
Our data suggest that the human endothelial plasma membrane contains an 18-to 21-Kd inhibitor of the terminal complement proteins that shares both functional and antigenic properties with the 18-to 21-Kd CSb-9-inhibitor, CD59, previously detected in the human erythrocyte and leukocyte plasma membrane. In erythrocytes, this protein appears to serve a key role in restricting the cytolytic consequence of C5b-9 assembly.12*16 In addition to contributing to the normal resistance of human endothelial cells to lysis by complement, our data suggest that this membrane component serves directly to attenuate the capacity of the C5b-9 proteins to evoke thrombogenic responses from these cells, which normally express predominantly anticoagulant properties.
When CSb67-containing endothelial cells were exposed to anti-CD59, C5b-9 pore formation (as indicated by 'H-DOG release, Fig 2) was enhanced fourfold, suggesting that this antigen limits C8 and C9 binding to C5b67 sites or limits subsequent activation of the pore. Similarly, anti-CD59 enhances hemolysis of CSb67-erythrocytes exposed to C8 and C9, and enhances secretion and prothrombinase activity of CSb67-platelets exposed to C8 plus C9. The protective effect of CD59 in CSb-9-mediated hemolysis appears to be related to this protein's capacity to limit the number of C9 that bind to C5b-8 deposited on the erythrocyte surface.I6 Human platelets exposed to anti-CD59 show exhanced susceptibility to the stimulatory effects of the C5b-9 complex and increased binding of C9 to C5b-8,I5 suggesting that epitopes recognized by anti-CD59 include a functional domain@) which interfere(s) with the binding and/or activation of C9 by membrane bound C5b-8. In endothelial cells, we did not observe increased C9 binding to C5b-8 on cells exposed to anti-CD59 (Fig 6) . One interpretation of these data is that in endothelial cells the cell surface complement regulatory protein(s) that are inhibited by anti-CD59 restrict a conformational change in the C5b-9 complex necessary for pore formation and cell activation, rather than reducing C9 binding to C5b-8 per se. Alternatively, we have demonstrated previously that C5b-9 induces the formation of membrane microparticles that are shed from the endothelial surface and contain the membrane-inserted CSb-9 protein^.^ It is likely, therefore, that our inability to detect increased binding of lZ5I-C9 to C5b-8 on anti-CD59-treated endothelial monolayers is related to a concomitant increase in this vesiculation of membrane-embedded C5b-9 complexes from the surface of these cells. Of note in platelets, increased membrane incorporation of C9 after exposure to anti-CD59 has been shown to be largely accounted for by C5b-9
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The capacity of anti-CD59 to potentiate the C5b-9-induced vWF secretion and prothrombinase activity of endothelial cells suggests that a deletion or inactivation of the membrane protein recognized by this antibody might potentiate the procoagulant response of these cells exposed to low For personal use only. on October 30, 2017. by guest www.bloodjournal.org From xenogeneic organ transplants, or in ameliorating hyperacute allograft rejection. and the excellent technical assistance of Elizabeth A. Smith, Darlene Schwartzott, and Janet Heuser. Factors Va, Xa, and prothrombin were generous gifts from Dr Charles T. Esmon (Oklahoma Medical Research Foundation), and MoAbs IF1 and 1F5 were generously provided by Drs Motowo Tomita (Showa University, Tokyo, Japan) and Hidechika Okada (Nagoya City University School of Medicine, Nagoya, Japan).
